Scott Cooper, MD
Neurology · Cumming, GANPI 1205843588
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $249,922 of the $282,933 with a category attached, or 88.3%. 60 manufacturers reported payments, led by AbbVie at 44.8% of the total. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,551 payments — averaging $182.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$127K
- Teva Pharmaceuticals USA, Inc.$101K
- UCB, Inc.$25K
- Corium, LLC$8K
- Avanir Pharmaceuticals, Inc.$5K
- Biogen$2K
- plus $15K from 54 others
Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$5K
What the payments were for
- Consulting fees$6,0352%
- Speaking & faculty fees$249,92288%
- Travel & lodging$1,3520%
- Food & beverage$25,1759%
- Education$4490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$282,933 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $170,748 |
| UbrelvyUbrogepant | 28 | $43,512 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $33,875 |
| GocovriAmantadine Hcl | 11 | $20,367 |
| Memantine Hcl ErMemantine Hcl | 264 | $19,381 |
| BriviactBrivaracetam | 13 | $18,447 |
| Topiramate ErTopiramate | 35 | $18,001 |
| QuliptaAtogepant | 16 | $17,505 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $16,504 |
| Nurtec OdtRimegepant Sulfate | 11 | $16,406 |
| Dalfampridine ErDalfampridine | 14 | $15,622 |
| RytaryCarbidopa/Levodopa | 11 | $15,559 |
| Nucynta ErTapentadol Hcl | 12 | $14,020 |
| Aspirin-Dipyridamole ErAspirin/Dipyridamole | 50 | $6,179 |
| XareltoRivaroxaban | 11 | $6,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $100,740 | $170,74824 claims |
| AbbVieUbrelvy, Qulipta | $126,686 | $61,01744 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $5,364 | $33,87521 claims |
| MDD US Operations, LLCGocovri | $468 | $20,36711 claims |
| UCB, Inc.Briviact | $25,309 | $18,44713 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $606 | $16,62623 claims |
| PfizerNurtec Odt | $998 | $16,40611 claims |
| Johnson & JohnsonXarelto | $261 | $6,16611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Cumming
- Peter FutrellCumming$34K
- Frank PuhalovichCumming$33K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.